LU LUPIN
Lupin Q4 2025
LULUPIN

Lupin Q4 FY25 results (Jan–Mar 2025) and concall

Healthcare · Concall AI · Call held 15 May 2025

Management summary

  • Lupin reported a stellar FY25 with strong revenue and EBITDA growth, driven by robust performance in the US and India markets.
  • Margin expansion was significant, and the company achieved a zero-debt status.
  • While adjacency businesses are still in investment phase and loss-making, the core business shows strong momentum with a focus on complex generics and chronic therapy areas.

Source: Inve concall analysis and management guidance record.

Highlights

  • FY25 revenue of USD 2.7 billion and EBITDA of USD 625 million, demonstrating strong growth momentum.

  • EBITDA margins expanded to 23.2% in Q4 FY25, with an adjusted core margin of 26% after accounting for adjacencies and PLI.

  • US business achieved 17% growth in FY25, driven by complex generics which now constitute 30% of US revenues.

  • India business grew 14% in FY25, with chronic share improving to 64% and a target of 69-70% by FY30.

What they filed

₹ Cr · quarterly
Line itemQ3 FY25Q4 FY25
Revenue4,208 4,486
EBITDA1,411 1,746
Net profit985 1,291
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Guidance & targets

India Business Growth

  • India market growth multiple India Business Growth · many years · High confidence 1.2-1.3 times the market

India Sales Force Expansion

  • Number of representatives added India Sales Force Expansion · every year · High confidence 400-500 representatives

Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.

Q&A highlights

2 direct
Impact of MFN policy on drug pricing Direct
I think the MFN would definitely impact the brand side of the business much more than the generic and the focus under IRA has been on the highest value drugs. So, it is really the highest value drugs that will likely get impacted. I think that at the end of the day the value of t

Clarifies management's view that MFN primarily targets branded drugs, not generics, and expects litigation to challenge it.

Asked by Kunal Lakhan

Flexibility for US manufacturing expansion and tariffs Direct
If there is a need to manufacture essential drugs in the US, we will explore it. We are actively exploring that with the National Security Council as part of the White House right now. The government has identified 9 drugs that they believe that are essential and we go into the d

Indicates willingness to expand US manufacturing if government incentives are provided, aligning with de-risking strategies.

Asked by Kunal Lakhan

Unlock risks & concerns, Q1 FY26 watchlist, and full call analysis

You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:

  • 6 risks, concerns & management red flags
  • 5 watchlist triggers for Q1 FY26
  • +11 more guidance targets & verbatim management quotes
  • +6 more analyst Q&A exchanges & evasion checks
  • Capital allocation & full section-by-section narrative

Sign in to use your monthly call allowance.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image